当前位置: X-MOL 学术ACS Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer
ACS Medicinal Chemistry Letters ( IF 3.5 ) Pub Date : 2023-01-23 , DOI: 10.1021/acsmedchemlett.2c00543
Robert B Kargbo 1
Affiliation  

ALDH1A3 is an important member of 19 aldehyde dehydrogenases, which metabolize reactive aldehydes to their corresponding carboxylic acids, detoxify endogenous and exogenous aldehydes, and are also involved in the biosynthesis of retinoic acid. In addition, ALDH1A3 plays important physiological and toxicological roles in different pathologies, including type II diabetes, obesity, cancer, pulmonary arterial hypertension, and neointimal hyperplasia. Consequently, inhibition of ALDH1A3 may offer new therapeutic options for patients with cancer, obesity, diabetes, and cardiovascular disorder.

中文翻译:


发现用于治疗癌症的选择性醛脱氢酶抑制剂



ALDH1A3是19种醛脱氢酶的重要成员,其将反应性醛代谢为相应的羧酸,对内源性和外源性醛进行解毒,还参与视黄酸的生物合成。此外,ALDH1A3 在不同的病理学中发挥着重要的生理和毒理学作用,包括 II 型糖尿病、肥胖、癌症、肺动脉高压和新内膜增生。因此,抑制 ALDH1A3 可能为癌症、肥胖、糖尿病和心血管疾病患者提供新的治疗选择。
更新日期:2023-01-23
down
wechat
bug